CN108699006B - 3-((杂-)芳基)-8-氨基-2-氧代-1,3-氮杂-螺-[4.5]-癸烷衍生物 - Google Patents

3-((杂-)芳基)-8-氨基-2-氧代-1,3-氮杂-螺-[4.5]-癸烷衍生物 Download PDF

Info

Publication number
CN108699006B
CN108699006B CN201780006506.5A CN201780006506A CN108699006B CN 108699006 B CN108699006 B CN 108699006B CN 201780006506 A CN201780006506 A CN 201780006506A CN 108699006 B CN108699006 B CN 108699006B
Authority
CN
China
Prior art keywords
cis
phenyl
diazaspiro
dimethylamino
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780006506.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN108699006A (zh
Inventor
S.屈纳特
R.M.克尼希斯
A.克莱斯
A.韦格特
I.科内齐基
P.拉特克利费
R.约施托克
T.科克
K.林茨
W.施勒德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Priority to CN202111487304.1A priority Critical patent/CN114149413A/zh
Publication of CN108699006A publication Critical patent/CN108699006A/zh
Application granted granted Critical
Publication of CN108699006B publication Critical patent/CN108699006B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41661,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201780006506.5A 2016-01-13 2017-01-13 3-((杂-)芳基)-8-氨基-2-氧代-1,3-氮杂-螺-[4.5]-癸烷衍生物 Active CN108699006B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111487304.1A CN114149413A (zh) 2016-01-13 2017-01-13 3-((杂)芳基)-8-氨基-2-氧代-1,3-氮杂-螺-[4.5]-癸烷衍生物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16151012.8 2016-01-13
EP16151012 2016-01-13
PCT/EP2017/025005 WO2017121647A1 (en) 2016-01-13 2017-01-13 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202111487304.1A Division CN114149413A (zh) 2016-01-13 2017-01-13 3-((杂)芳基)-8-氨基-2-氧代-1,3-氮杂-螺-[4.5]-癸烷衍生物

Publications (2)

Publication Number Publication Date
CN108699006A CN108699006A (zh) 2018-10-23
CN108699006B true CN108699006B (zh) 2021-11-05

Family

ID=55129633

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780006506.5A Active CN108699006B (zh) 2016-01-13 2017-01-13 3-((杂-)芳基)-8-氨基-2-氧代-1,3-氮杂-螺-[4.5]-癸烷衍生物
CN202111487304.1A Pending CN114149413A (zh) 2016-01-13 2017-01-13 3-((杂)芳基)-8-氨基-2-氧代-1,3-氮杂-螺-[4.5]-癸烷衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202111487304.1A Pending CN114149413A (zh) 2016-01-13 2017-01-13 3-((杂)芳基)-8-氨基-2-氧代-1,3-氮杂-螺-[4.5]-癸烷衍生物

Country Status (30)

Country Link
US (7) US20170197970A1 (https=)
EP (2) EP3722284B1 (https=)
JP (2) JP6893516B2 (https=)
KR (2) KR102768715B1 (https=)
CN (2) CN108699006B (https=)
AR (2) AR107434A1 (https=)
AU (1) AU2017206908B2 (https=)
BR (1) BR112018014305B1 (https=)
CA (1) CA3011176C (https=)
CL (1) CL2018001911A1 (https=)
CO (1) CO2018008447A2 (https=)
CY (1) CY1122923T1 (https=)
DK (2) DK3722284T3 (https=)
EA (2) EA202190281A1 (https=)
EC (1) ECSP18060834A (https=)
ES (2) ES3014458T3 (https=)
FI (1) FI3722284T3 (https=)
HR (2) HRP20200782T1 (https=)
HU (2) HUE049771T2 (https=)
IL (2) IL260496B (https=)
LT (2) LT3402781T (https=)
MX (1) MX378607B (https=)
PE (1) PE20221732A1 (https=)
PL (2) PL3722284T3 (https=)
PT (2) PT3402781T (https=)
RS (2) RS60307B1 (https=)
SI (2) SI3722284T1 (https=)
TW (1) TWI635082B (https=)
WO (1) WO2017121647A1 (https=)
ZA (1) ZA201805356B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3402784T1 (sl) * 2016-01-13 2020-07-31 Gruenenthal Gmbh Derivati 3-((hetero)aril)-alkil-8-amino-2-okso-1,3-diaza-spiro-(4.5)-dekana
SI3402782T1 (sl) 2016-01-13 2020-11-30 Grunenthal Gmbh 8-amino-2-okso-1,3-diaza-spiro-(4,5)-dekanski derivati
CA3011176C (en) 2016-01-13 2023-09-19 Grunenthal Gmbh 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
CA3011180A1 (en) 2016-01-13 2017-07-20 Grunenthal Gmbh 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
US10961242B2 (en) * 2017-05-17 2021-03-30 Legochem Biosciences, Inc. Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same
BR112021013557A2 (pt) 2019-01-11 2021-09-21 Grünenthal GmbH Amidas de pirrolidina substituídas iii
CN110862395B (zh) * 2019-11-13 2020-09-29 株洲千金药业股份有限公司 一种制备他达拉非重要杂质的原料化合物的制备方法
US20240400537A1 (en) 2023-04-25 2024-12-05 Gruenenthal Gmbh Cis-8-(3,5-difluorophenyl)-8-(dimethylamino)-1,3-diazaspiro[4.5]decan-2-one derivatives

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043967A1 (de) * 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische cyclohexan-derivate
WO2009118168A1 (de) * 2008-03-27 2009-10-01 Grünenthal GmbH Substituierte 4-aminocyclohexan-derivate

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2734265B1 (fr) 1995-05-17 1997-06-13 Adir Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant
RU2268883C2 (ru) 2001-04-18 2006-01-27 Эро-Селтик, С.А. Аналоги ноницептина и фармацевтическая композиция на их основе
DE10130020A1 (de) 2001-06-25 2003-12-04 Gruenenthal Gmbh Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate
DE10210195B4 (de) 2002-03-07 2005-12-15 Schwarz Pharma Ag Verwendung von 1,3-Diazaspiro-[4,5]decan-2,4-dithion zur Behandlung von Schmerz
DK1519939T5 (da) 2002-07-05 2011-01-24 Targacept Inc N-Aryl-diazaspirocykliske forbindelser og fremgangsmåder til fremstilling og anvendelse deraf
EP1628978A2 (en) 2003-05-23 2006-03-01 Zealand Pharma A/S Triaza-spiro compounds as nociceptin analogues and uses thereof
JO2676B1 (en) 2004-04-06 2012-06-17 جانسين فارماسوتيكا ان. في Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines
DE102005044813A1 (de) 2005-05-19 2007-10-04 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102005023784A1 (de) 2005-05-19 2006-11-30 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102005030051A1 (de) 2005-06-27 2006-12-28 Grünenthal GmbH Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102006019597A1 (de) 2006-04-27 2007-10-31 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
CN101553474B (zh) 2006-10-19 2013-02-27 霍夫曼-拉罗奇有限公司 作为糖尿病用11b-HSD1抑制剂的咪唑啉酮和咪唑烷酮衍生物
EP2121624A1 (en) * 2007-02-01 2009-11-25 Glaxo Group Limited Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
CA2683598C (en) 2007-04-09 2015-11-17 Janssen Pharmaceutica Nv 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the orl-i receptor for the treatment of anxiety and depression
TW201038572A (en) 2009-03-25 2010-11-01 Gruenenthal Gmbh Substituted spiro-amide compounds
WO2010151815A2 (en) 2009-06-25 2010-12-29 Abbott Laboratories 3,9-diazaspiro[5,5]undecane amides and ureas and methods of use thereof
TWI582092B (zh) 2010-07-28 2017-05-11 歌林達股份有限公司 順式-四氫-螺旋(環己烷-1,1’-吡啶[3,4-b]吲哚)-4-胺-衍生物
WO2015192039A1 (en) 2014-06-13 2015-12-17 Purdue Pharma L.P. Heterocyclic morphinan derivatives and use thereof
AR107354A1 (es) 2016-01-13 2018-04-18 Bristol Myers Squibb Co Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock
CA3011180A1 (en) 2016-01-13 2017-07-20 Grunenthal Gmbh 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
SI3402811T1 (sl) 2016-01-13 2022-06-30 Novo Nordisk A/S Analogi EGF(A) z maščobnokislinskimi substituenti
CA3011176C (en) 2016-01-13 2023-09-19 Grunenthal Gmbh 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
BR112018014302B1 (pt) 2016-01-13 2023-10-17 Grünenthal GmbH Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
SI3402782T1 (sl) 2016-01-13 2020-11-30 Grunenthal Gmbh 8-amino-2-okso-1,3-diaza-spiro-(4,5)-dekanski derivati
SI3402784T1 (sl) * 2016-01-13 2020-07-31 Gruenenthal Gmbh Derivati 3-((hetero)aril)-alkil-8-amino-2-okso-1,3-diaza-spiro-(4.5)-dekana

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043967A1 (de) * 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische cyclohexan-derivate
WO2009118168A1 (de) * 2008-03-27 2009-10-01 Grünenthal GmbH Substituierte 4-aminocyclohexan-derivate

Also Published As

Publication number Publication date
AU2017206908B2 (en) 2020-07-09
CY1122923T1 (el) 2021-10-29
SI3402781T1 (sl) 2020-10-30
EA202190281A1 (ru) 2021-09-01
FI3722284T3 (fi) 2025-03-14
BR112018014305A2 (pt) 2018-12-11
KR102719137B1 (ko) 2024-10-21
US20170197970A1 (en) 2017-07-13
RS66559B1 (sr) 2025-03-31
CA3011176A1 (en) 2017-07-20
ECSP18060834A (es) 2018-08-31
US20190106429A1 (en) 2019-04-11
JP2019501937A (ja) 2019-01-24
NZ745185A (en) 2024-03-22
TWI635082B (zh) 2018-09-11
PT3722284T (pt) 2025-03-07
HUE070444T2 (hu) 2025-06-28
TW201730156A (zh) 2017-09-01
ZA201805356B (en) 2021-04-28
PL3402781T3 (pl) 2020-09-21
EP3402781B1 (en) 2020-03-04
RS60307B1 (sr) 2020-07-31
MX378607B (es) 2025-03-11
US20210032256A1 (en) 2021-02-04
PE20221732A1 (es) 2022-11-07
HUE049771T2 (hu) 2020-10-28
DK3402781T5 (da) 2020-06-02
KR20180097732A (ko) 2018-08-31
AR107434A1 (es) 2018-05-02
US10807988B2 (en) 2020-10-20
EP3722284B1 (en) 2025-01-22
KR102768715B1 (ko) 2025-02-18
CN108699006A (zh) 2018-10-23
EA201891611A1 (ru) 2019-01-31
CA3011176C (en) 2023-09-19
LT3402781T (lt) 2020-06-10
PL3722284T3 (pl) 2025-03-31
KR20240070681A (ko) 2024-05-21
US20180201616A1 (en) 2018-07-19
CO2018008447A2 (es) 2018-08-31
HRP20200782T1 (hr) 2020-08-21
US20190375754A1 (en) 2019-12-12
JP6893516B2 (ja) 2021-06-23
IL285355B1 (en) 2023-01-01
PT3402781T (pt) 2020-07-07
WO2017121647A1 (en) 2017-07-20
HRP20250176T1 (hr) 2025-04-11
AR124672A2 (es) 2023-04-19
EP3402781A1 (en) 2018-11-21
CN114149413A (zh) 2022-03-08
EP3722284A1 (en) 2020-10-14
US20230303573A1 (en) 2023-09-28
MX2018008643A (es) 2018-11-19
ES3014458T3 (en) 2025-04-22
IL285355B2 (en) 2023-05-01
JP2021091716A (ja) 2021-06-17
US20210188860A1 (en) 2021-06-24
JP7148660B2 (ja) 2022-10-05
LT3722284T (lt) 2025-02-25
BR112018014305B1 (pt) 2023-10-17
ES2807549T3 (es) 2021-02-23
SI3722284T1 (sl) 2025-04-30
EA037598B1 (ru) 2021-04-20
IL260496B (en) 2021-09-30
CL2018001911A1 (es) 2018-10-19
IL285355A (en) 2021-09-30
AU2017206908A1 (en) 2018-08-30
DK3722284T3 (da) 2025-03-10
DK3402781T3 (da) 2020-05-18

Similar Documents

Publication Publication Date Title
CN108699006B (zh) 3-((杂-)芳基)-8-氨基-2-氧代-1,3-氮杂-螺-[4.5]-癸烷衍生物
CN108602778B (zh) 8-氨基-2-氧代-1,3-二氮杂-螺-[4.5]-癸烷衍生物
CN108699005B (zh) 3-(羧基乙基)-8-氨基-2-氧代-1,3-氮杂-螺-[4.5]-癸烷衍生物
CN108779075B (zh) 3-(羧基甲基)-8-氨基-2-氧代-1,3-氮杂-螺-[4.5]-癸烷衍生物
HK40036373A (en) 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
HK40036373B (en) 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
HK40035886A (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
HK1260520A1 (en) 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
HK1260520B (en) 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
EA045034B1 (ru) Производные 3-((гетеро-)арил)-8-амино-2-оксо-1,3-диаза-спиро-[4,5]-декана
HK1260528A1 (en) 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
HK1260528B (en) 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant